AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
288.01B
Market cap288.01B
Price-Earnings ratio
27.70
Price-Earnings ratio27.70
Dividend yield
1.69%
Dividend yield1.69%
Average volume
1.74M
Average volume1.74M
High today
$187.07
High today$187.07
Low today
$184.65
Low today$184.65
Open price
$185.87
Open price$185.87
Volume
1.25M
Volume1.25M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

AstraZeneca(AZN) stock is priced at $185.57, giving the company a market capitalization of 288.01B. It carries a P/E multiple of 27.70 and pays a dividend yield of 1.7%.

On 2026-05-31, AstraZeneca(AZN) stock traded between a low of $184.65 and a high of $187.07. Shares are currently priced at $185.57, which is +0.5% above the low and -0.8% below the high.

AstraZeneca(AZN) shares are trading with a volume of 1.25M, against a daily average of 1.74M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

AZN News

Nasdaq 13h
Velan Capital Drops 140,000 Mineralys Therapeutics Shares Worth $4.1 Million

Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $...

Velan Capital Drops 140,000 Mineralys Therapeutics Shares Worth $4.1 Million
TipRanks 2d
AstraZeneca Prostate Cancer Study in Russia Paused, Nudging Real‑World Data Timeline

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst rating...

TipRanks 3d
CSPC Receives US$1.2 Billion Upfront from AstraZeneca in Peptide Drug Alliance

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

82%

of 28 ratings
Buy
82.1%
Hold
10.7%
Sell
7.1%

More AZN News

TipRanks 3d
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint - TipRanks

...

AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint - TipRanks
TipRanks 3d
CelLBxHealth strikes AstraZeneca services deal for CTC-powered analytics

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 3d
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 3d
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients

The company states: “AstraZeneca’s (AZN) IMFINZI – or durvalumab – in combination with Bacillus Calmette-Guerin – BCG – induction and maintenance therapy has be...

TipRanks 3d
AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer

AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of ad...

TipRanks 3d
AstraZeneca Advances Camizestrant Combo Trial in Advanced Breast Cancer

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst r...

TipRanks 3d
AstraZeneca Bolsters Ovarian Cancer Strategy With Fresh Real-World Study Update

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst rating...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.